Climate Change Data

Mayne Pharma Group Limited

Climate Impact & Sustainability Data (2023)

Reporting Period: 2023

Environmental Metrics

ESG Focus Areas

  • Environmental
  • Social
  • Governance

Environmental Achievements

  • Aim to reduce scope 1 and 2 greenhouse gas emissions
  • Increase energy efficiency and use renewable sources where feasible
  • Continue to reduce the environmental impact of active pharmaceutical ingredients
  • Reduce the overall mass of packaging materials per unit dose and increase the proportion of recycled and responsibly sourced materials
  • Reduce water usage annually and use wastewater recycling opportunities where feasible

Social Achievements

  • Launched NEXTSTELLIS® oral contraceptive in Australia
  • Launched initiative with GoodRx to increase awareness of NEXTSTELLIS® oral contraceptive in the US and expand access to birth control
  • Contributes to community activities financially, in-kind and by donating time
  • Supports several not-for-profit organisations
  • Supports and recognises researchers and young scientists
  • Provides training and development opportunities for staff and encourages a supportive and inclusive culture

Governance Achievements

  • Completed several significant and complex transactions requiring extensive modifications to Mayne Pharma’s systems, processes, and business model
  • Implemented a Risk Management Policy with a detailed, structured approach to systematically identify, rank, mitigate, and monitor risks
  • Adopted the ASX Corporate Governance Council 4th Edition Corporate Governance Principles and Recommendations

Climate Goals & Targets

Short-term Goals:
  • Deliver growth in existing businesses without significant capital for acquisitions
  • Complete integration of licensed women’s health portfolio, increasing sales, improving net selling prices, and managing cost infrastructure
  • Achieve profitable run rate for NEXTSTELLIS® in 1HFY24, with continued growth throughout FY24
  • Launch low strength BIJUVA® in the second half of FY24
  • Refine Dermatology channel strategy
  • Improve International segment performance with new manufacturing revenue streams and targeted investments

Environmental Challenges

  • Lack of market acceptance of NEXTSTELLIS®
  • Unsuccessful implementation of dermatology distribution channel
  • Inability to meet educational and scientific engagement needs of the healthcare community
  • Inherent competition risk to portfolio
  • Higher than expected channel inventory, co-pay charges, and industry pricing pressure in Dermatology
  • Gross to net impacts in Women's Health
  • Manufacturing performance issues in International segment
Mitigation Strategies
  • Refreshed sales leadership and marketing strategies for NEXTSTELLIS®
  • Refined our Dermatology channel strategy to drive better market access for patients and prescribers
  • Detailed inventory confirmations, roll forward calculations, more rigorous analytics in Dermatology
  • Business improvement program in International segment focusing on improving operating efficiency and identifying new commercial opportunities
  • Disciplined and risk-balanced product selection process
  • Strong systems and processes to monitor and manage the performance of each product and customer relationship
  • Developing business models and systems to move closer to patients
  • Diversify channels to market

Supply Chain Management

Responsible Procurement
  • Increase the proportion of recycled and responsibly sourced materials across the supply chain

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: ASX Corporate Governance Council 4th Edition